Filtered By:
Vaccination: Veterinary Vaccinations
This page shows you your search results in order of date.
Order by Relevance | Date
Total 6987 results found since Jan 2013.
Evaluation the effect of dietary vitamin E, sesamin and thymoquinone bioactive compounds on immunological response, intestinal traits and MUC-2 gene expression in broiler Japanese quails ( < em > Coturnix japonica < /em > )
Anim Biotechnol. 2023 Sep 20:1-11. doi: 10.1080/10495398.2023.2259437. Online ahead of print.ABSTRACTThe current study was performed to determine the effect of dietary vitamin E, sesamin and thymoquinone bioactive lignans derived from sesame and black seed on immunological response, intestinal traits and Mucin2 gene expression in broiler quails. Three hundred and fifty (one days-old) quails were allotted to seven dietary treatments with five replicates as an experimental randomized design study. Treatments were basal diet as a control, control +100 and +200 mg of vitamin E, sesamin and thymoquinone per each kg of diet resp...
Source: Animal Biotechnology - September 20, 2023 Category: Biotechnology Authors: Yaser Rahimian Farshid Kheiri Mostafa Faghani Source Type: research
Correlative CD4 and CD8 T-cell immunodominance in humans and mice: Implications for preclinical testing
In this study, we addressed this matter by analyzing experimentally identified epitopes based on published data curated in the Immune Epitopes DataBase (IEDB) database. We first analyzed SARS-CoV-2 spike (S) and nucleoprotein (N), which are two common targets of the immune response and well studied in both human and mouse systems. We observed a weak but statistically significant correlation between human and H-2b mouse T-cell responses (CD8 S specific (r = 0.206, p = 1.37 × 10-13); CD4 S specific (r = 0.118, p = 2.63 × 10-5) and N specific (r = 0.179, p = 2.55 × 10-4)). Due to intrinsic differences in MHC molecules acro...
Source: Cellular and Molecular Immunology - September 19, 2023 Category: Molecular Biology Authors: Tertuliano Alves Pereira Neto John Sidney Alba Grifoni Alessandro Sette Source Type: research
Preclinical evaluation of a SARS-CoV-2 variant B.1.351-based candidate DNA vaccine
Vaccine. 2023 Sep 17:S0264-410X(23)01091-5. doi: 10.1016/j.vaccine.2023.09.021. Online ahead of print.ABSTRACTThe SARS-CoV-2 pandemic revealed the critical shortfalls of global vaccine availability for emergent pathogens and the need for exploring additional vaccine platforms with rapid update potential in response to new variants. Thus, it remains essential, for the present evolving SARS-CoV-2/Covid-19 and future pandemics, to continuously develop and characterize new and different vaccine platforms. Here, we describe an expression-optimized DNA vaccine candidate based on the SARS-CoV-2 spike protein of the Beta variant (...
Source: Vaccine - September 19, 2023 Category: Allergy & Immunology Authors: Ria Lassauni ère Charlotta Polacek Jeanette Linnea Tingstedt Anders Fomsgaard Source Type: research
Correlative CD4 and CD8 T-cell immunodominance in humans and mice: Implications for preclinical testing
In this study, we addressed this matter by analyzing experimentally identified epitopes based on published data curated in the Immune Epitopes DataBase (IEDB) database. We first analyzed SARS-CoV-2 spike (S) and nucleoprotein (N), which are two common targets of the immune response and well studied in both human and mouse systems. We observed a weak but statistically significant correlation between human and H-2b mouse T-cell responses (CD8 S specific (r = 0.206, p = 1.37 × 10-13); CD4 S specific (r = 0.118, p = 2.63 × 10-5) and N specific (r = 0.179, p = 2.55 × 10-4)). Due to intrinsic differences in MHC molecules acro...
Source: Cellular and Molecular Immunology - September 19, 2023 Category: Molecular Biology Authors: Tertuliano Alves Pereira Neto John Sidney Alba Grifoni Alessandro Sette Source Type: research
Preclinical evaluation of a SARS-CoV-2 variant B.1.351-based candidate DNA vaccine
Vaccine. 2023 Sep 17:S0264-410X(23)01091-5. doi: 10.1016/j.vaccine.2023.09.021. Online ahead of print.ABSTRACTThe SARS-CoV-2 pandemic revealed the critical shortfalls of global vaccine availability for emergent pathogens and the need for exploring additional vaccine platforms with rapid update potential in response to new variants. Thus, it remains essential, for the present evolving SARS-CoV-2/Covid-19 and future pandemics, to continuously develop and characterize new and different vaccine platforms. Here, we describe an expression-optimized DNA vaccine candidate based on the SARS-CoV-2 spike protein of the Beta variant (...
Source: Vaccine - September 19, 2023 Category: Allergy & Immunology Authors: Ria Lassauni ère Charlotta Polacek Jeanette Linnea Tingstedt Anders Fomsgaard Source Type: research
Evaluation of an iELISA for detection and quantification of rabies antibodies in domestic dog sera
Vaccine. 2023 Sep 14:S0264-410X(23)01058-7. doi: 10.1016/j.vaccine.2023.09.004. Online ahead of print.ABSTRACTMany rabies endemic-countries have recognized rabies as a public health problem that can be eliminated. As a result, some countries have started implementing small-scale vaccination programs with the aim of scaling them up. Post-vaccination serological monitoring is crucial to assess the efficacy of these programs. The recommended serological tests, the rapid fluorescent focus inhibition test, and the fluorescent antibody virus neutralization (FAVN) are accurate; however, the procedures require considerable experti...
Source: Vaccine - September 16, 2023 Category: Allergy & Immunology Authors: Ahmed Lugelo Katie Hampson Lorraine M McElhinney Felix Lankester Source Type: research
Efficacy and immunogenicity of a veterinary vaccine candidate against tick-borne encephalitis in dogs
Vaccine. 2023 Sep 14:S0264-410X(23)01089-7. doi: 10.1016/j.vaccine.2023.09.019. Online ahead of print.ABSTRACTTick-borne encephalitis (TBE) is a severe neuroinfection of humans. Dogs are also commonly infected with tick-borne encephalitis virus (TBEV). These infections are usually asymptomatic, but sometimes show clinical signs similar to those seen in humans and can be fatal. To date, there is no TBEV vaccine available for use in dogs. To address this need, a TBEV vaccine candidate for dogs based on inactivated whole virus antigen was developed. The safety, immunogenicity, and efficacy of the vaccine candidate were tested...
Source: Vaccine - September 16, 2023 Category: Allergy & Immunology Authors: Jiri Salat Milan Hunady Pavel Svoboda Lucie Strelcova Petra Strakova Andrea Fortova Martin Palus Daniel Ruzek Source Type: research
Evaluation of an iELISA for detection and quantification of rabies antibodies in domestic dog sera
Vaccine. 2023 Sep 14:S0264-410X(23)01058-7. doi: 10.1016/j.vaccine.2023.09.004. Online ahead of print.ABSTRACTMany rabies endemic-countries have recognized rabies as a public health problem that can be eliminated. As a result, some countries have started implementing small-scale vaccination programs with the aim of scaling them up. Post-vaccination serological monitoring is crucial to assess the efficacy of these programs. The recommended serological tests, the rapid fluorescent focus inhibition test, and the fluorescent antibody virus neutralization (FAVN) are accurate; however, the procedures require considerable experti...
Source: Vaccine - September 16, 2023 Category: Allergy & Immunology Authors: Ahmed Lugelo Katie Hampson Lorraine M McElhinney Felix Lankester Source Type: research
Efficacy and immunogenicity of a veterinary vaccine candidate against tick-borne encephalitis in dogs
Vaccine. 2023 Sep 14:S0264-410X(23)01089-7. doi: 10.1016/j.vaccine.2023.09.019. Online ahead of print.ABSTRACTTick-borne encephalitis (TBE) is a severe neuroinfection of humans. Dogs are also commonly infected with tick-borne encephalitis virus (TBEV). These infections are usually asymptomatic, but sometimes show clinical signs similar to those seen in humans and can be fatal. To date, there is no TBEV vaccine available for use in dogs. To address this need, a TBEV vaccine candidate for dogs based on inactivated whole virus antigen was developed. The safety, immunogenicity, and efficacy of the vaccine candidate were tested...
Source: Vaccine - September 16, 2023 Category: Allergy & Immunology Authors: Jiri Salat Milan Hunady Pavel Svoboda Lucie Strelcova Petra Strakova Andrea Fortova Martin Palus Daniel Ruzek Source Type: research
Mini Review on Clinical Aspects of Monkeypox
Curr Pharm Biotechnol. 2023 Sep 14. doi: 10.2174/1389201025666230914094444. Online ahead of print.ABSTRACTMonkeypox is a disease caused by the monkeypox virus, which is a type of orthopox virus that comes from the virus family Poxviridae. Its first case reported in animals and humans was in 1958 and 1970, respectively. It is a viral zoonosis disease with two modes of transmission: animal to human (via direct contact or eating the meat of an infected animal) and human to human (via contact or contact with skin lesions, body fluids, and infected person's contaminated objects). The literature depicts that monkeypox is less co...
Source: Current Pharmaceutical Biotechnology - September 15, 2023 Category: Biotechnology Authors: Yash Saraswat Kamal Shah Source Type: research
Advancements in Nipah virus treatment: Analysis of current progress in vaccines, antivirals, and therapeutics
Immunology. 2023 Sep 15. doi: 10.1111/imm.13695. Online ahead of print.ABSTRACTNipah virus (NiV) causes severe encephalitis in humans. Three NiV strains NiV-Malaysia (NiVM ), NiV Bangladesh (NiVB ), and NiV India (NiVI reported in 2019) have been circulating in South-Asian nations. Sporadic outbreak observed in South-East Asian countries but human to human transmission raises the concern about its pandemic potential. The presence of the viral genome in reservoir bats has further confirmed that NiV has spread to the African and Australian continents. NiV research activities have gained momentum to achieve specific preparedn...
Source: Immunology - September 15, 2023 Category: Allergy & Immunology Authors: Gayatree Mishra Vishal Prajapat Debasis Nayak Source Type: research
Mini Review on Clinical Aspects of Monkeypox
Curr Pharm Biotechnol. 2023 Sep 14. doi: 10.2174/1389201025666230914094444. Online ahead of print.ABSTRACTMonkeypox is a disease caused by the monkeypox virus, which is a type of orthopox virus that comes from the virus family Poxviridae. Its first case reported in animals and humans was in 1958 and 1970, respectively. It is a viral zoonosis disease with two modes of transmission: animal to human (via direct contact or eating the meat of an infected animal) and human to human (via contact or contact with skin lesions, body fluids, and infected person's contaminated objects). The literature depicts that monkeypox is less co...
Source: Current Pharmaceutical Biotechnology - September 15, 2023 Category: Biotechnology Authors: Yash Saraswat Kamal Shah Source Type: research
